Broad Clinical-Stage Pipeline
BioNTech mRNA Technology
Platform Studies Indication Phase Status
MERIT Melanoma Phase I Completed
FixVAC Lipo-MERIT Melanoma Phase I Recruiting Fixed combination of shared antigens
HARE-40* Head and Neck Cancer Phase I/II Recruiting
RNA-WAREHOUSE IRIS Breast Cancer Phase I Not yet recruiting Personalized combination of shared antigens
IVAC® MUTANOME IVAC® Melanoma Phase I Completed Individualized Vaccines Against Cancer
Increasingly individualized Increasingly Triple Negative IVAC® MUTANOME TNBC-MERIT Phase I Recruiting Individualized Vaccines Against Cancer Breast Cancer
IVAC® MUTANOME Genentech / BioNTech Multiple Indications Phase I / PoC Recruiting Individualized Vaccines Against Cancer
BioNTech Cell & Gene Therapies
Cell & Gene CAR T cells Ovarian Cancer Phase I Not yet recruiting
BioNTech Protein Therapeutics
Antibodies IAPACA* Pancreatic Cancer Phase I/II Not yet recruiting
BioNTech Small Molecules Pioneering Individualized Small Molecules TLR Agonist Solid Tumors Phase I Not yet recruiting Cancer Therapies *Studies performed in collaboration with academic partners within the frame of the EU consortium immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) Company Overview PlatformS
BioNTech is the largest private biopharmaceutical company in Europe. Pharmacologically optimized protein coding The Company was founded to address major challenges in the cancer space: RNA for targeted in vivo delivery mRNA Technology • Cancer immunotherapies the need for effective, truly individualized treatments and the willingness to • Prophylactic vaccines provide life-long, comprehensive support to patients. In short, BioNTech’s • Protein replacement mission is to transform cancer into a manageable, non-lethal disease. Immunotherapy with genetically engineered T cells, adoptive T cell transfer Cell & Gene Therapy The clinical-stage Company is fully integrated and combines all building • T cell receptor therapies • CAR therapies blocks of immunotherapy under one roof to bring highly potent, tailormade Engineered nanoparticles for cancer immunotherapy and individualized cancer therapies to market. Over the next decade, it is • Bispecific antibodies Protein Therapeutics anticipated that the treatment paradigm will evolve so that each patient • Microbodies • Virus-like particles receives customized treatment manufactured just in time. Through its Small molecule drug discovery diversified technology platforms, in-house diagnostics and manufacturing • TLR-agonists Small Molecules units, BioNTech is well-positioned to advance its mission. • Immuno-modulating small molecules • Drug discovery services
Individualized mRNA Immunology Quick Facts Key Collaborations Concepts – BioNTech´s IVAC® Platform Employees: 50:50 cost and profit share. Novel mRNA-based, 650 Employees individualized cancer vaccines IVAC® MUTANOME: BioNTech is the first company BioNTech’s initial product-to-market offerings of individualized cancer - treat (as of October 2017) $310m in upfront and near-term payments. worldwide: ments are developed using the Company’s mRNA technology platform. The Corporate Co-development, co-commercialization. Headquarters: IVAC® (Individualized Vaccines Against Cancer) platform enables the design of mRNA cancer immunotherapies: $60m upfront An der Goldgrube 12 1. to undertake clinical trials with immunotherapies targeting cancer mutations and therefore has the potential 55131 Mainz and near-term milestones. Germany • an mRNA-based individualized cancer vaccine targeting neo-antigens to be universally applicable across cancer types. BioNTech has developed three 50:50 cost and profit share. Bispecific antibodies: • an intravenous formulation of an mRNA vaccine Management $15m in upfront and near-term payments. different concepts with increasing degrees of individualization which allow Team: • an mRNA-based individualized vaccine drawn from a warehouse efficiency in designing custom-made therapeutic vaccines for every single Prof. Dr. Ugur Sahin, Licensing agreements. Novel tumor targets and Co-Founder & CEO of mRNAs encoding cancer-selective antigens patient, tailored to his or her needs as well as tumor characteristics. Sean Marett, COO corresponding T cell receptors: $30m upfront, Dr. Sierk Poetting, CFO $30m equity investment in BioNTech Cell & Gene Therapies GmbH. 2. to implement a medical genomics-driven and GMP-approved Key Investors: manufacturing process for individual patient-specific therapies BioNTech AG Strüngmann Co-development, co-commercialization. An der Goldgrube 12 Family Office Specifically for animal health applications. 55131 Mainz, Germany MIG Fonds Salvia GmbH +49 6131 – 9084 – 0 Manufacturing collaboration. Fully automated and [email protected] digitalized manufacturing facility for development www.biontech.de of mRNA-based therapeutic cancer vaccines.